European Journal of Surgical Oncology
Volume 35, Issue 2 , Pages 113-122 , February 2009

Neoadjuvant chemotherapy for locally advanced breast cancer: A review of the literature and future directions

  • J. Mathew

      Affiliations

    • Professorial Unit of Surgery, Nottingham University Hospital (City hospital Campus), Hucknall Road, Nottingham NG5 1PB, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 115 926 8993.
    • ,
  • K.S. Asgeirsson

      Affiliations

    • Professorial Unit of Surgery, Nottingham University Hospital (City hospital Campus), Hucknall Road, Nottingham NG5 1PB, UK
    • ,
  • K.L. Cheung

      Affiliations

    • Professorial Unit of Surgery, Nottingham University Hospital (City hospital Campus), Hucknall Road, Nottingham NG5 1PB, UK
    • ,
  • S. Chan

      Affiliations

    • Department of Clinical Oncology, Nottingham University Hospital (City hospital Campus), Nottingham, UK
    • ,
  • A. Dahda

      Affiliations

    • Department of Clinical Oncology, Nottingham University Hospital (City hospital Campus), Nottingham, UK
    • ,
  • J.F.R. Robertson

      Affiliations

    • Professorial Unit of Surgery, Nottingham University Hospital (City hospital Campus), Hucknall Road, Nottingham NG5 1PB, UK

,Accepted 28 March 2008.

References 

  1. Wolff AC, Davidson NE. Preoperative therapy in breast cancer: Lessons from the treatment of locally advanced disease. Oncologist. 2002;7:239–245
  2. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–3636
  3. West Midlands Cancer Intelligence Unit. 0–10 year relative survival for cases of breast cancer by stage diagnosed in the West Midlands 1985–1989 followed up to the end of 1999, as at January 2002.
  4. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. SEER Program public use data tapes 1973–1998, November 2000 Submission. Issued: April 2001.
  5. Haagensen CD, Stout AP. Carcinoma of breast. II. Criteria of operability. Ann Surg. 1943;118:859–868
  6. Williams MR, Gilson D, Marsh L, et al. The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer. Eur J Surg Oncol. 1988;14:235–240
  7. Rubens RD, Bartelink H, Engelsman E, et al. Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC breast cancer co-operative group trial (10792). Eur J Cancer Clin Oncol. 1989;25:667–678
  8. Tan SM, Cheung KL, Willsher PC, Blamey RW, Chan SY, Robertson JFR. Locally advanced primary breast tumour: medium-term results of a randomised controlled trial of multimodal therapy versus initial hormone therapy. Eur J Cancer. 2001;37:2331–2338
  9. Willsher PC, Robertson JFR, Chan SY, Jackson L, Blamey RW. Locally advanced breast cancer: Early results of a randomised trial of multimodal therapy versus initial hormone therapy. Eur J Cancer. 1997;33:45–49
  10. De Lena M, Zucali R, Viganotti G, et al. Combined chemotherapy- radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemotherapy Pharmacol. 1978;1:53–59
  11. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine year results from National Surgical Adjuvant Breast and Bowel project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102
  12. Heys SD, Hutcheon AW, Sarkar TK, et al. on behalf of the Aberdeen breast group. Neoadjuvant Docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer Suppl. 2002;3(suppl):69–74
  13. Thomas E, Homes FA, Smith TL, et al. The use of alternative, non-cross resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomised trial. J Clin Oncol. 2004;22:2294–2302
  14. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized Phase III trial comparing cyclophosphamide, Epirubicin, and Flurouracil with a dose intensified epirubicin and cyclophosphamide+Filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol. 2003;21:843–850
  15. Semiglazov VF, Semigloazov VV, Dashyan GA, et al. Phase 2 randomised trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110:244–254
  16. Ezzat AA, Ibrahim EM, Ajarim DS, et al. Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer. 2004;90:968–974
  17. Matteis AD, Nuzzo F, D'Aiuto G, et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment inpatients with large operable or locally advanced carcinoma of the breast. Cancer. 2002;94:895–901
  18. Lebowitz PF, Eng-Wong J, Swain SM, et al. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res. 2004;10:6764–6769
  19. Espinosa E, Morales S, Borrega P, et al. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemother Pharmacol. 2004;54:546–552
  20. Kao J, Conzen S, Jaskowiak N, Song D, et al. Concomitant radiation therapy and pacitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys. 2005;61:1045–1053
  21. Tham Y, Gomez LF, Mohsin S, et al. Clinical response to neoadjuvant docetaxel predics improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005;94:279–284
  22. Gradishhar W, Wedam B, Jahanzeb M, et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol. 2005;16:1297–1304
  23. Kuerer H, Newman L, Smith T, et al. Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–469
  24. Clark J, Roseman J, Cance W, Halle J, Graham M. Extending the indications for breast-conserving treatment to patients with locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 1998;42:345–350
  25. Shen J, Valero V, Buchholz TA, et al. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol. 2004;11:854–860
  26. Huang E, Tucker S, Strom E, et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:351–357
  27. Baldini E, Gardin G, Evangelista G, Prochio T, Collecchi P, Lionetto R. Long term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer. 2004;5:358–363
  28. Erol K, Baltali E, Altundag K, et al. Neoadjuvant chemotherapy with cyclophosphamide, methotrexate and 5-flurouracil in locally advanced breast cancer. Onkologie. 2005;28:81–85
  29. Kim R, Osaki A, Tanabe K, Toge T. Neoadjuvant chemotherapy for local advanced breast cancer with stage III B. Oncology Rep. 2004;11:1265–1272
  30. McIntosh S, Ogston K, Payne S, et al. Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy. Am J Surg. 2003;185:525–531
  31. Favret A, Carlson R, Goffinet D, Jeffrey S, Dirbas F, Stockdale F. Locally advanced breast cancer: Is surgery necessary?. Breast J. 2001;7:131–137
  32. Asoglu O, Muslumanoglu M, Igci A, et al. Breast conservation surgery after primary chemotherapy in locally advanced breast cancer. Acta Chir Belg. 2005;105:62–68
  33. Colozza M, Gori S, Mosconi AM, et al. Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long term results. Am J Clin Oncol. 1996;19:10–17
  34. Gajdos C, Tartter P, Estabrook A, et al. Relationship of clinical and pathological response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol. 2002;80:4–11
  35. Bear DB, Anderson S, Brown A, et al. The effect on tumour response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide; Preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2003;21:4165–4174
  36. Bear DB, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project B-27. J Clin Oncol. 2006;24:2019–2027
  37. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676–2685
  38. von Minckwitz G, Blohmer J-U, Raab G, et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol. 2005;16(1):56–63
  39. Gianni L, Semiglazov V, Manikhas GM, et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol. 2007;25(18 suppl):532
  40. Buzdar A, Valero V, Ibrahim N, et al. Neoadjuvant therapy with paclitaxel followed by 5-flurouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent tratuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomised study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007;13:228–233
  41. Rugo HS. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist. 2004;9:43–49
  42. Lyons JA, Silverman P, Remick S, et al. Toxicity results and early outcome data on a randomised phase II study of docetaxel+or − bevacizumab for locally advanced, unrespectable breast cancer. J Clin Oncol. 2006;24:3049;(Abstract)
  43. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2006;18:1927–1934
  44. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–10874
  45. Early Breast Cancer Trialists collaborative group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomised trials. Lancet. 2005;365:1687–1717
  46. Rouzier R, Pusztai L, Delaloge S, et al. Nomograms to predict pathologic complete response and metastasis free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005;23:8331–8339
  47. Mathieu M-C, Rouzier R, Llombart-Cussac A, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer. 2004;40:342–351
  48. Cristofanilli M, Gonzalez-Angulo A, Sneige N. Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23:41–48
  49. Hutcheon AW, Heys SD, Sarkar TK, et al. Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Res Treat. 2003;82(Suppl 1):S9;(Abstract 11)
  50. Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer. Cancer. 1995;76:1491–1512
  51. Pierga JY, Mouret E, Dieras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer. 2000;83:1480–1487
  52. Veronesi U, Bonadonna G, Zurrida S, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg. 1995;222:612–618
  53. Rouzier R, Extra J, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumours and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 2002;20:1304–1310
  54. Kuerer H, Newman L, Buzdar MD, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998;176:502–509
  55. Van der Hage JA, Van der Hage CJH, Julian J, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol. 2001;19:4224–4237
  56. Mieog JSD, van der Hage JA. van de Velde CJH. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94:1189–1200
  57. Clouth B, Chandrasekharan S, Inwang R, Smith S, Davidson N, Sauven P. The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer. Eur J Surg Oncol. 2007;33:961–966
  58. Mueiac L, MacGorgan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast cancer larger than 3 cm: A unicentre randomized trial with a 124-month median follow up. Ann Oncol. 1999;10:47–52
  59. Scholl SM, Pierga JY, Asselain B, et al. Breast cancer response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer. 1995;31A:1969–1975
  60. Broet P, Scholl SM, De La Rochefordiere A, et al. Short and long term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomised trial. Breast Cancer Res Treat. 1999;58:151–156
  61. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–2685
  62. Semiglazlov VF, Topuzov EE, Bavli JL, et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb–IIIa breast cancer. Ann Oncol. 1998;9:1179–1184
  63. Powles TJ, Hickish TF, Markis A. Randomised trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995;13:547–552
  64. Makris A, Powles TJ, Ashley SE, et al. A reduction in requirements for mastectomy in a randomised trial of neoadjuvant chemoendocrine therapy in breast cancer. Ann Oncol. 1998;9:1179–1184
  65. Gardin G, Rosso R, Campora E, et al. Locally advanced non-metastatic breast cancer: Analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. Eur J Cancer. 1995;31A:1428–1433
  66. Von Minckwitz G, Costa SD, Eiermann W, et al. Maximized reduction of primary breast tumour size using pre-operative chemotherapy with doxorubicin and docetaxel. J Clin Oncol. 1999;17:1999–2005
  67. Banadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: Eight year experience at Milan cancer institute. J Clin Oncol. 1998;16:93–100
  68. Khanna M, Mark R, Silverstein M, et al. Breast conservation management of breast tumours 4 cm or larger. Arch Surg. 1992;127:1038–1043
  69. Asgeirsson KS, McCulley SJ, Pinder SE, Macmillan RD. Size of invasive breast cancer and risk of local recurrence after breast conservation therapy. Eur J Cancer. 2003;39(17):2462–2469
  70. Edeiken BS, Fornage BD, Bedi DG, et al. US-guided implantation of metallic markers for permanent localization of the tumour bed in patients with breast cancer who undergo preoperative chemotherapy. Radiology. 1999;213:895–900
  71. Mumtaz H, Hall-Craggs MA, Davidson T, et al. Staging of symptomatic primary breast cancer with MR imaging. AJR Am J Roentgenol. 1997;169:417–424
  72. Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of preoperative contrast-enhancement MR imaging on the therapeutic approach. Radiology. 1992;213:881–888
  73. Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol. 2002;179:1193–1199
  74. Garimella V, Qutob O, Fox JN, et al. Recurrences rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. Eur J Surg Oncol. 2007;33:157–161
  75. Kim S-J, Kim S-K, Lee E, et al. Predictive value of (18F) FDG PRT for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol. 2004;15:1352–1357

PII: S0748-7983(08)00116-9

doi: 10.1016/j.ejso.2008.03.015

European Journal of Surgical Oncology
Volume 35, Issue 2 , Pages 113-122 , February 2009

Article Tools